Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four Analyses of Randomized Clinical Trials.

Background: Several studies have investigated the effect of direct oral anticoagulants (DOACs) in Latin American patients with atrial fibrillation (AF), but the results remain controversial. Therefore, we aimed to compare the efficacy and safety of DOACs vs. warfarin in Latin American patients with AF.

Methods: We systematically searched the PubMed and Embase databases until November 2021 for studies that compared the effect of DOACs vs. warfarin in Latin patients with AF. Adjusted hazard ratios (HRs) and 95% CIs were pooled by a random-effects model using an inverse variance method.

Results: Four analyses of randomized clinical trials (RCTs) involving 42,411 DOACs and 29,270 warfarin users were included. In Latin American patients with AF, for the effectiveness outcomes, the use of DOACs compared with warfarin was significantly associated with decreased risks of stroke or systemic embolism (SSE) (HR = 0.78; 95%CI.64-0.96), stroke (HR = 0.75; 95%CI.57-0.99), hemorrhagic stroke (HR = 0.14; 95%CI.05-0.36), all-cause death (HR = 0.89; 95% CI.80-1.00), but not ischemic stroke and cardiovascular death. For the safety outcomes, compared with warfarin, the use of DOACs was associated with reduced risks of major or non-major clinically relevant (NMCR) bleeding (HR = 0.70; 95% CI.57-0.86), major bleeding (HR = 0.70; 95%CI.53-0.92), intracranial hemorrhage (ICH) (HR = 0.42; 95%CI.24-0.74), or any bleeding (HR = 0.70;95% CI.62-0.78), but not gastrointestinal bleeding. In non-Latin American patients with AF, for the effectiveness outcomes, the use of DOACs compared with warfarin was significantly associated with decreased risks of SSE (HR = 0.87; 95%CI.75-1.00), hemorrhagic stroke (HR = 0.41; 95%CI.28-0.60), cardiovascular death (HR = 0.87; 95% CI.81-0.94), all-cause death (HR = 0.90; 95% CI.85-0.94). Conversely, the risk of myocardial infarction increased (HR = 1.34; 95% CI 1.13-1.60), but not ischemic stroke. For the safety outcomes, compared with warfarin, the use of DOACs was associated with reduced risks of major or NMCR bleeding (HR = 0.75; 95%CI.61-0.92), major bleeding (HR = 0.76; 95%CI.63-0.92), ICH (HR = 0.42; 95%CI.36-0.52), and any bleeding (HR = 0.81; 95% CI.71-0.92), but not gastrointestinal bleeding.

Conclusion: Current pooled data from the four analyses of RCTs suggested that compared with warfarin, DOACs appeared to have significant reductions in SSE, stroke, hemorrhagic stroke, all-cause death, major or NMCR bleeding, major bleeding, ICH, and any bleeding, but comparable risks of ischemic stroke, cardiovascular death, and gastrointestinal bleeding in Latin American patients with AF. DOACs appeared to have significant reductions in SSE, hemorrhagic stroke, all-cause death, cardiovascular death, major or NMCR bleeding, major bleeding, ICH, and any bleeding, and increased the risk of myocardial infarction, but comparable risks of stroke, ischemic stroke, and gastrointestinal bleeding in non-Latin American patients with AF.